Identifying the optimal dose of cannabidiol by intrabuccal administration in Kramnik (C3HeB/FeJ) mice
- PMID: 39957386
- DOI: 10.1002/ame2.12569
Abstract
Background: Cannabidiol (CBD) has numerous therapeutic properties, and is used to treat neurological conditions, such as neuroinflammation. However, the optimal dose of CBD to penetrate the brain requires further investigation. The primary aim of this study was to use a mouse model and the intrabuccal route for CBD administration to determine the optimal dose at which CBD can penetrate the brain. The secondary aim was to determine whether sex is a confounding factor.
Methods: Thirty adult Kramnik mice, divided equally into three groups, were administered CBD oil intrabuccally at three doses-10, 20, and 30 mg/kg, euthanized 6 h later, and whole brain, urine, and blood samples were collected. Liquid chromatography with tandem mass spectrometry was used to analyze the collected samples.
Results: CBD and its three metabolites-7-carboxy cannabidiol (7-COOH-CBD), 7-hydroxy cannabidiol (7-OH-CBD) and 6-hydroxy cannabidiol (6-OH-CBD), were identified and quantified in all samples. The 10 and 20 mg/kg doses of CBD produced similar results in the brain, but the group given the 10 mg/kg dose had the least variation. The 30 mg/kg dose yielded the highest abundance of CBD and its metabolites in all samples, but also the greatest variation. Sex only became a confounding factor at 30 mg/kg.
Conclusions: This study shows that the intrabuccal route of CBD administration is reliable and the 10 mg/kg dose of CBD is recommended in mice because there were good CBD metabolite concentrations in all samples, with the least variation among the doses, and sex was not a confounder at 10 mg/kg.
Keywords: C3HeB/FeJ mice; LC–MS/MS; brain; cannabidiol (CBD); dosage; intrabuccal administration.
© 2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
References
REFERENCES
-
- Stasiłowicz A, Tomala A, Podolak I, Cielecka‐Piontek J. Cannabis sativa L. as a natural drug meeting the criteria of a multitarget approach to treatment. Int J Mol Sci. 2021;2:778. doi:10.3390/ijms22020778
-
- Liu Y, Xiao A‐P, Cheng H, et al. Phytochemical differences of hemp (Cannabis sativa L.) leaves from different germplasms and their regulatory effects on lipopolysaccharide‐induced inflammation in Matin‐Darby canine kidney cell lines. Front Nutr. 2022;9:902625. doi:10.3389/fnut.2022.902625
-
- Flores‐Sanchez IJ, Verpoorte R. Secondary metabolism in cannabis. Phytochem Rev. 2008;7:615‐639. doi:10.1007/s11101-008-9094-4
-
- Pénzes Z, Alimohammadi S, Horváth D, et al. The dual role of cannabidiol on monocyte‐derived dendritic cell differentiation and maturation. Front Immunol. 2023;14:1240800. doi:10.3389/fimmu.2023.1240800
-
- Chagas MH, Eckeli A, Zuardi AW, et al. Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;5:564‐566. doi:10.1111/jcpt.12179

